Non-communicable diseases, especially cardiovascular diseases (CVD), have become more prevalent across the world, more so in developing countries. Novel methods in the management of CVD risks in patients with diabetes mellitus, type 2 (DM2) requires constant attention and an ever-evolving approach. The role of magnesium supplementation in the management of CVD has been described, but the relationship between serum magnesium (Mg) and the lipid subsets have had conflicting results in different population groups. Methods: A cross-sectional study was performed by collecting data on patients with DM2 from a specialised diabetes clinic at

Background: Diabetes mellitus (DM) poses a great burden of disease worldwide. The adverse effects of hypomagnesaemia (hypoMg 2+ ) in patients with DM have been well described, with a higher prevalence of hypoMg 2+ in patients with DM than in the general population (up to 35% vs. up to 15%) ) and renal function are presented for statistical analysis. Results: A total of 744 patients were enrolled. Most patients were female (527; 70.8%) and were diagnosed with Type 2 diabetes (DM2) (633; 85.1%) with a mean age of 52.3 (SD 15.6 years). The prevalence of hypoMg 2+ was found to be 8.44%. HypoMg 2+ was associated with poor glycaemic control (r = -0.16, p < 0.0001). A significant relationship was observed between glycaemic control and hypoMg 2+ in males (r = -0.21, p = 0.0038), but not females (r = -0.011, p = 0.81). No significant relationship was evident between hypoMg 2+ and renal dysfunction (r = -0.064, p = 0.11). Conclusion: HypoMg 2+ in patients with DM was associated with poorer glycaemic control in the male population, potentially increasing the risk of adverse health outcomes. However, the prevalence of hypoMg 2+ was not higher than in published data, but population-specific controls are required. No association could be found between hypoMg 2+ and renal dysfunction. The need for routine Mg 2+ testing and supplementation in our population requires further assessment.